Evidence map›Paper›PMID 40465241›Full record

ArticleThe oncologist2025

Qualitative study of patient and caregiver experiences during multimodality treatment for locally advanced rectal cancer.

Kelsey S Lau-Min, Riley Psenka, Mia Holtze, Katina Massad, Andrea Hansen, Stephen B Lo, Areej El-Jawahri, Jennifer S Temel, Aparna Parikh, Ryan Nipp and 1 more

Abstract read
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kelsey S Lau-MinDivision of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States.ORCID 0000-0001-8854-224X
Riley PsenkaCancer Outcomes Research and Education Program, Massachusetts General Hospital Cancer Center, Boston, MA 02114, United States.
Mia HoltzeCancer Outcomes Research and Education Program, Massachusetts General Hospital Cancer Center, Boston, MA 02114, United States.
Katina MassadCancer Outcomes Research and Education Program, Massachusetts General Hospital Cancer Center, Boston, MA 02114, United States.
Andrea HansenDivision of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States.
Stephen B LoCancer Outcomes Research and Education Program, Massachusetts General Hospital Cancer Center, Boston, MA 02114, United States.
Areej El-JawahriDivision of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States.
Jennifer S TemelDivision of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States.
Aparna ParikhDivision of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States.ORCID 0000-0002-5245-7841
Ryan NippCancer Outcomes Research and Education Program, Massachusetts General Hospital Cancer Center, Boston, MA 02114, United States.ORCID 0000-0002-4577-3248
Lara TraegerCancer Outcomes Research and Education Program, Massachusetts General Hospital Cancer Center, Boston, MA 02114, United States.

Funding

Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9M
Dianne and Kevin WeinfeldNIH HHS K12CA087723
6 · The paper itself

Abstract

backgroundLocally advanced rectal cancer (LARC) is treated with combined chemotherapy, radiation, and surgery to maximize the potential for cure. This multimodality treatment approach can result in substantial toxicity for patients, including life-altering changes in bowel, urinary, and sexual function as well as decrements in quality of life (QOL). We explored the lived experiences of patients and caregivers during multimodality treatment for LARC.

methodsWe conducted a qualitative study of patients undergoing multimodality treatment for LARC and their designated caregivers. Each participant completed an hour-long individual in-depth interview using a semistructured interview guide covering treatment experiences, coping strategies, and supportive care needs. We transcribed, coded, and analyzed interviews using a thematic analysis approach and constant comparison methods.

resultsWe included 21 patients (median age 51 years, 11 women, 17 white, 10 post-surgical resection) and 10 caregivers (6 married/living with patients). We identified five themes among patients and caregivers: (1) the lengthy, complex, and unpredictable nature of multimodality therapy; (2) need to balance receiving detailed information with avoiding information overload; (3) the profound impact that multimodality therapy had on multiple QOL domains; (4) use of coping mechanisms to maintain control and preserve identity; and (5) desire for additional informational and supportive care resources.

conclusionPatients and caregivers face important challenges in navigating care for LARC due to the complicated and unpredictable nature of multimodality therapy. Findings from this study should inform the development of interventions to address the immense informational and supportive care needs of patients receiving multimodality treatment for LARC.

Indexed as

CaregiversRectal NeoplasmsAdaptation, PsychologicalAdultAgedCombined Modality TherapyFemaleHumansMaleMiddle AgedQualitative ResearchQuality of Lifecombined modality therapyqualitative researchrectal cancersupportive care

Identifiers

PMID40465241
PMCPMC12135775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.